| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Dystrophies, Limb-Girdle | 6 | 2020 | 22 | 2.050 |
Why?
|
| Pregnancy | 28 | 2025 | 2362 | 1.960 |
Why?
|
| Premature Birth | 6 | 2025 | 114 | 1.650 |
Why?
|
| Placenta Diseases | 4 | 2021 | 9 | 1.590 |
Why?
|
| Lead | 3 | 2024 | 45 | 1.560 |
Why?
|
| Placenta | 5 | 2021 | 68 | 1.540 |
Why?
|
| Pre-Eclampsia | 4 | 2022 | 70 | 1.450 |
Why?
|
| Infertility, Female | 8 | 2021 | 47 | 1.420 |
Why?
|
| Stillbirth | 3 | 2025 | 18 | 1.370 |
Why?
|
| Mothers | 4 | 2023 | 278 | 1.330 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2021 | 15 | 1.330 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2025 | 50 | 1.330 |
Why?
|
| Ischemia | 3 | 2020 | 203 | 1.200 |
Why?
|
| Sex Offenses | 4 | 2024 | 43 | 1.190 |
Why?
|
| Fertilization in Vitro | 4 | 2021 | 83 | 1.080 |
Why?
|
| Female | 54 | 2025 | 33804 | 1.050 |
Why?
|
| Oocyte Donation | 4 | 2019 | 7 | 1.040 |
Why?
|
| Genetic Variation | 3 | 2026 | 389 | 0.980 |
Why?
|
| Aneuploidy | 2 | 2023 | 42 | 0.980 |
Why?
|
| Obstetrics | 3 | 2024 | 88 | 0.940 |
Why?
|
| Transcription Factor TFIIIA | 1 | 2025 | 7 | 0.910 |
Why?
|
| Humans | 72 | 2025 | 64768 | 0.890 |
Why?
|
| Golgi Apparatus | 1 | 2025 | 65 | 0.880 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2025 | 94 | 0.870 |
Why?
|
| Lead Poisoning | 1 | 2024 | 10 | 0.870 |
Why?
|
| Infertility | 3 | 2020 | 30 | 0.860 |
Why?
|
| Counseling | 2 | 2024 | 375 | 0.860 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2025 | 81 | 0.850 |
Why?
|
| Cell Movement | 3 | 2025 | 478 | 0.840 |
Why?
|
| Prenatal Diagnosis | 1 | 2023 | 40 | 0.790 |
Why?
|
| Adult | 30 | 2025 | 17251 | 0.790 |
Why?
|
| Focus Groups | 2 | 2024 | 319 | 0.780 |
Why?
|
| Prenatal Care | 3 | 2022 | 169 | 0.770 |
Why?
|
| Infant, Small for Gestational Age | 4 | 2025 | 25 | 0.770 |
Why?
|
| Embryo Transfer | 2 | 2021 | 24 | 0.750 |
Why?
|
| Genetic Testing | 1 | 2023 | 140 | 0.750 |
Why?
|
| Cesarean Section | 4 | 2024 | 100 | 0.730 |
Why?
|
| Reproductive Techniques, Assisted | 4 | 2017 | 34 | 0.730 |
Why?
|
| Maternal Health Services | 1 | 2022 | 60 | 0.710 |
Why?
|
| Muscle Weakness | 3 | 2018 | 33 | 0.700 |
Why?
|
| Sexual and Gender Minorities | 4 | 2024 | 75 | 0.700 |
Why?
|
| Breast Feeding | 1 | 2023 | 164 | 0.670 |
Why?
|
| Emotions | 1 | 2023 | 228 | 0.670 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2021 | 48 | 0.660 |
Why?
|
| Rape | 1 | 2020 | 14 | 0.660 |
Why?
|
| Placental Circulation | 1 | 2020 | 1 | 0.660 |
Why?
|
| Placental Insufficiency | 1 | 2020 | 3 | 0.650 |
Why?
|
| Depression, Postpartum | 1 | 2022 | 120 | 0.620 |
Why?
|
| Communication | 2 | 2023 | 595 | 0.600 |
Why?
|
| Bone and Bones | 1 | 2020 | 152 | 0.590 |
Why?
|
| Bereavement | 3 | 2024 | 18 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 5 | 2023 | 354 | 0.570 |
Why?
|
| Pregnancy Complications | 3 | 2024 | 381 | 0.570 |
Why?
|
| Infant, Newborn | 7 | 2025 | 1410 | 0.560 |
Why?
|
| Tripartite Motif Proteins | 1 | 2018 | 42 | 0.560 |
Why?
|
| Infant | 7 | 2023 | 1679 | 0.560 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 2017 | 8 | 0.540 |
Why?
|
| alpha-Glucosidases | 1 | 2017 | 10 | 0.540 |
Why?
|
| Risk Factors | 9 | 2022 | 5392 | 0.520 |
Why?
|
| Community Health Centers | 2 | 2017 | 98 | 0.520 |
Why?
|
| Retrospective Studies | 11 | 2024 | 6818 | 0.510 |
Why?
|
| Tissue Donors | 2 | 2017 | 146 | 0.510 |
Why?
|
| Gingival Neoplasms | 1 | 2016 | 2 | 0.510 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 66 | 0.500 |
Why?
|
| Infant Mortality | 1 | 2016 | 20 | 0.500 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 226 | 0.490 |
Why?
|
| Hypertension | 1 | 2022 | 606 | 0.490 |
Why?
|
| Self Concept | 2 | 2017 | 119 | 0.480 |
Why?
|
| Gestational Age | 5 | 2025 | 192 | 0.470 |
Why?
|
| Depression | 2 | 2022 | 893 | 0.440 |
Why?
|
| Botswana | 5 | 2025 | 5 | 0.440 |
Why?
|
| Young Adult | 11 | 2024 | 4772 | 0.430 |
Why?
|
| Family Planning Services | 1 | 2014 | 21 | 0.420 |
Why?
|
| Mutation, Missense | 4 | 2020 | 190 | 0.420 |
Why?
|
| Contraception Behavior | 1 | 2014 | 37 | 0.410 |
Why?
|
| Qualitative Research | 5 | 2024 | 745 | 0.410 |
Why?
|
| Tissue and Organ Procurement | 1 | 2013 | 39 | 0.400 |
Why?
|
| Students | 4 | 2024 | 225 | 0.400 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2023 | 22 | 0.400 |
Why?
|
| Disclosure | 2 | 2022 | 57 | 0.390 |
Why?
|
| Attitude to Health | 2 | 2014 | 295 | 0.380 |
Why?
|
| Antihypertensive Agents | 2 | 2025 | 178 | 0.360 |
Why?
|
| Stress, Psychological | 4 | 2017 | 474 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2023 | 128 | 0.360 |
Why?
|
| Child | 9 | 2024 | 4554 | 0.360 |
Why?
|
| Anemia | 2 | 2023 | 132 | 0.360 |
Why?
|
| Progesterone | 2 | 2024 | 165 | 0.360 |
Why?
|
| Sperm Banks | 1 | 2011 | 2 | 0.350 |
Why?
|
| Male | 22 | 2024 | 30840 | 0.350 |
Why?
|
| Mass Screening | 3 | 2024 | 695 | 0.350 |
Why?
|
| Spermatozoa | 1 | 2013 | 267 | 0.340 |
Why?
|
| Policy | 1 | 2011 | 56 | 0.340 |
Why?
|
| Placenta Growth Factor | 2 | 2021 | 17 | 0.340 |
Why?
|
| Placenta Accreta | 2 | 2021 | 2 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2021 | 25 | 0.330 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 105 | 0.330 |
Why?
|
| Actinin | 2 | 2021 | 11 | 0.330 |
Why?
|
| Transcription Factors | 1 | 2018 | 1550 | 0.320 |
Why?
|
| Adolescent | 11 | 2024 | 6247 | 0.320 |
Why?
|
| Fetal Death | 2 | 2020 | 15 | 0.310 |
Why?
|
| Live Birth | 2 | 2020 | 21 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 767 | 0.290 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2008 | 6 | 0.290 |
Why?
|
| Virus Attachment | 1 | 2008 | 18 | 0.290 |
Why?
|
| Parturition | 2 | 2022 | 53 | 0.290 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 20 | 0.290 |
Why?
|
| Universities | 4 | 2024 | 168 | 0.280 |
Why?
|
| Vagina | 1 | 2008 | 87 | 0.280 |
Why?
|
| Cohort Studies | 4 | 2023 | 2604 | 0.270 |
Why?
|
| Anxiety | 2 | 2023 | 422 | 0.260 |
Why?
|
| Papillomavirus Infections | 1 | 2008 | 133 | 0.250 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 2690 | 0.250 |
Why?
|
| Mental Health | 3 | 2024 | 361 | 0.250 |
Why?
|
| Sorghum | 1 | 2026 | 2 | 0.240 |
Why?
|
| Crops, Agricultural | 1 | 2026 | 3 | 0.240 |
Why?
|
| Genome, Plant | 1 | 2026 | 5 | 0.240 |
Why?
|
| Delivery, Obstetric | 2 | 2016 | 55 | 0.240 |
Why?
|
| Middle Aged | 14 | 2020 | 18156 | 0.230 |
Why?
|
| Child, Preschool | 4 | 2020 | 2042 | 0.230 |
Why?
|
| Nucleoside Q | 1 | 2025 | 1 | 0.230 |
Why?
|
| Fetal Viability | 1 | 2024 | 5 | 0.210 |
Why?
|
| Muscle, Skeletal | 3 | 2018 | 770 | 0.210 |
Why?
|
| Cerclage, Cervical | 1 | 2024 | 4 | 0.210 |
Why?
|
| Membrane Transport Proteins | 1 | 2025 | 134 | 0.210 |
Why?
|
| Genome, Chloroplast | 1 | 2024 | 2 | 0.210 |
Why?
|
| Diatoms | 1 | 2024 | 2 | 0.210 |
Why?
|
| Progestins | 1 | 2024 | 29 | 0.210 |
Why?
|
| RNA, Transfer | 1 | 2025 | 93 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 716 | 0.210 |
Why?
|
| Genome, Mitochondrial | 1 | 2024 | 13 | 0.210 |
Why?
|
| Sulfonic Acids | 1 | 2024 | 11 | 0.210 |
Why?
|
| Polyphenols | 1 | 2024 | 61 | 0.210 |
Why?
|
| Maltose | 1 | 2023 | 12 | 0.210 |
Why?
|
| Phenotype | 4 | 2026 | 1227 | 0.210 |
Why?
|
| Stilbenes | 1 | 2024 | 22 | 0.210 |
Why?
|
| Cervix Uteri | 2 | 2024 | 58 | 0.200 |
Why?
|
| Ferric Compounds | 1 | 2023 | 42 | 0.200 |
Why?
|
| HeLa Cells | 1 | 2025 | 541 | 0.200 |
Why?
|
| Lysosomes | 2 | 2023 | 167 | 0.200 |
Why?
|
| Case-Control Studies | 3 | 2022 | 1123 | 0.200 |
Why?
|
| Mutation | 4 | 2022 | 2656 | 0.200 |
Why?
|
| Gravidity | 2 | 2021 | 11 | 0.190 |
Why?
|
| Obstetric Labor, Premature | 2 | 2020 | 30 | 0.190 |
Why?
|
| Fertility | 2 | 2020 | 84 | 0.190 |
Why?
|
| Self Care | 1 | 2024 | 214 | 0.190 |
Why?
|
| Pregnancy Rate | 2 | 2021 | 31 | 0.190 |
Why?
|
| Protein Biosynthesis | 1 | 2025 | 331 | 0.190 |
Why?
|
| Phosphorylation | 1 | 2025 | 959 | 0.190 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 402 | 0.190 |
Why?
|
| Birth Weight | 1 | 2022 | 83 | 0.180 |
Why?
|
| Gynecology | 2 | 2021 | 55 | 0.180 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2022 | 22 | 0.180 |
Why?
|
| RNA Isoforms | 1 | 2022 | 6 | 0.180 |
Why?
|
| Homozygote | 2 | 2020 | 122 | 0.180 |
Why?
|
| Gender Identity | 1 | 2022 | 68 | 0.180 |
Why?
|
| Dystroglycans | 2 | 2018 | 4 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2020 | 3297 | 0.180 |
Why?
|
| Genomics | 2 | 2026 | 383 | 0.180 |
Why?
|
| Pinocytosis | 1 | 2021 | 4 | 0.170 |
Why?
|
| United States | 9 | 2021 | 8052 | 0.170 |
Why?
|
| Intellectual Disability | 1 | 2024 | 176 | 0.170 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 17 | 0.170 |
Why?
|
| Ovulation Induction | 1 | 2021 | 14 | 0.170 |
Why?
|
| Illinois | 1 | 2020 | 13 | 0.170 |
Why?
|
| Cell Proliferation | 1 | 2025 | 1035 | 0.170 |
Why?
|
| Sterol Esterase | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2020 | 6 | 0.160 |
Why?
|
| Mental Health Services | 1 | 2024 | 302 | 0.160 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2020 | 3 | 0.160 |
Why?
|
| Filamins | 1 | 2020 | 8 | 0.160 |
Why?
|
| Stromal Cells | 1 | 2021 | 78 | 0.160 |
Why?
|
| Lipid Droplets | 1 | 2020 | 34 | 0.160 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 21 | 0.160 |
Why?
|
| RNA | 1 | 2024 | 425 | 0.160 |
Why?
|
| Dynamin II | 1 | 2020 | 1 | 0.160 |
Why?
|
| Exome | 1 | 2020 | 69 | 0.160 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2020 | 25 | 0.160 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 148 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2022 | 188 | 0.160 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 151 | 0.150 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 2751 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5590 | 0.150 |
Why?
|
| Curriculum | 2 | 2024 | 604 | 0.150 |
Why?
|
| Recurrence | 1 | 2021 | 654 | 0.150 |
Why?
|
| Freezing | 1 | 2019 | 21 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 625 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2020 | 222 | 0.150 |
Why?
|
| Grief | 3 | 2024 | 19 | 0.150 |
Why?
|
| Cryopreservation | 1 | 2019 | 30 | 0.150 |
Why?
|
| Choanal Atresia | 1 | 2018 | 3 | 0.140 |
Why?
|
| Microphthalmos | 1 | 2018 | 3 | 0.140 |
Why?
|
| Blastocyst | 1 | 2019 | 74 | 0.140 |
Why?
|
| Parity | 3 | 2022 | 71 | 0.140 |
Why?
|
| Nose | 1 | 2018 | 27 | 0.140 |
Why?
|
| Autophagy | 1 | 2020 | 231 | 0.140 |
Why?
|
| Health Equity | 1 | 2019 | 54 | 0.140 |
Why?
|
| Glycosylation | 1 | 2018 | 138 | 0.140 |
Why?
|
| Muscular Diseases | 1 | 2018 | 50 | 0.140 |
Why?
|
| Maternal-Child Health Centers | 1 | 2017 | 3 | 0.140 |
Why?
|
| Heterozygote | 1 | 2018 | 172 | 0.140 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2018 | 44 | 0.140 |
Why?
|
| Mannosyltransferases | 1 | 2017 | 10 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2018 | 117 | 0.130 |
Why?
|
| Distal Myopathies | 1 | 2017 | 6 | 0.130 |
Why?
|
| Founder Effect | 1 | 2017 | 10 | 0.130 |
Why?
|
| Protein Kinases | 1 | 2018 | 152 | 0.130 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 11 | 0.130 |
Why?
|
| Connectin | 1 | 2017 | 14 | 0.130 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 746 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2011 | 493 | 0.130 |
Why?
|
| Gingiva | 1 | 2016 | 8 | 0.130 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2016 | 9 | 0.130 |
Why?
|
| Aortic Coarctation | 1 | 2016 | 12 | 0.120 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 182 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 200 | 0.120 |
Why?
|
| Eye Abnormalities | 1 | 2016 | 21 | 0.120 |
Why?
|
| Pregnancy Outcome | 3 | 2025 | 197 | 0.120 |
Why?
|
| Labor, Induced | 1 | 2016 | 26 | 0.120 |
Why?
|
| Incidence | 1 | 2020 | 1410 | 0.120 |
Why?
|
| Contraception | 2 | 2014 | 72 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2020 | 2090 | 0.120 |
Why?
|
| Labor, Obstetric | 1 | 2016 | 35 | 0.120 |
Why?
|
| Brain | 2 | 2022 | 1589 | 0.120 |
Why?
|
| Self Report | 1 | 2017 | 391 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 230 | 0.110 |
Why?
|
| Social Support | 2 | 2016 | 391 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 283 | 0.110 |
Why?
|
| Poverty | 1 | 2016 | 301 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2016 | 126 | 0.110 |
Why?
|
| Pregnancy in Adolescence | 1 | 2014 | 21 | 0.110 |
Why?
|
| Sex Education | 1 | 2014 | 27 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2017 | 1008 | 0.100 |
Why?
|
| Aged | 4 | 2018 | 14882 | 0.100 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2025 | 103 | 0.100 |
Why?
|
| Boston | 1 | 2014 | 257 | 0.100 |
Why?
|
| Caregivers | 1 | 2016 | 292 | 0.100 |
Why?
|
| Diet | 1 | 2016 | 533 | 0.100 |
Why?
|
| HIV Infections | 1 | 2020 | 953 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2021 | 5765 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 434 | 0.090 |
Why?
|
| Cervical Length Measurement | 2 | 2024 | 6 | 0.090 |
Why?
|
| Parents | 1 | 2016 | 410 | 0.090 |
Why?
|
| Iron | 2 | 2023 | 150 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 1431 | 0.090 |
Why?
|
| Physicians | 1 | 2017 | 473 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1564 | 0.090 |
Why?
|
| Cell Line | 4 | 2021 | 2019 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 2231 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 62 | 0.090 |
Why?
|
| Family | 1 | 2013 | 242 | 0.090 |
Why?
|
| Reproductive History | 1 | 2011 | 17 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1553 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2019 | 805 | 0.090 |
Why?
|
| Mice | 4 | 2025 | 11071 | 0.080 |
Why?
|
| Religion and Medicine | 1 | 2010 | 20 | 0.080 |
Why?
|
| Calcium Channels | 1 | 2010 | 103 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 285 | 0.080 |
Why?
|
| Exercise | 1 | 2016 | 960 | 0.080 |
Why?
|
| Neoplasms | 1 | 2020 | 1363 | 0.070 |
Why?
|
| Intention | 1 | 2009 | 73 | 0.070 |
Why?
|
| Polysaccharide-Lyases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Polyglycolic Acid | 1 | 2009 | 18 | 0.070 |
Why?
|
| Intracellular Space | 1 | 2009 | 33 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 176 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 225 | 0.070 |
Why?
|
| Lactic Acid | 1 | 2009 | 75 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2008 | 73 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2011 | 880 | 0.070 |
Why?
|
| Heparin | 1 | 2008 | 118 | 0.070 |
Why?
|
| Capsid | 1 | 2008 | 102 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 504 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 869 | 0.060 |
Why?
|
| Calcium | 1 | 2010 | 581 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2024 | 1574 | 0.060 |
Why?
|
| Animals | 4 | 2025 | 21264 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2009 | 410 | 0.060 |
Why?
|
| Plant Breeding | 1 | 2026 | 3 | 0.060 |
Why?
|
| Gene Flow | 1 | 2026 | 7 | 0.060 |
Why?
|
| Plant Leaves | 1 | 2026 | 22 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 586 | 0.060 |
Why?
|
| Domestication | 1 | 2026 | 5 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2026 | 28 | 0.060 |
Why?
|
| Reference Standards | 1 | 2026 | 76 | 0.060 |
Why?
|
| Nitriles | 1 | 2026 | 82 | 0.060 |
Why?
|
| Multigene Family | 1 | 2026 | 106 | 0.060 |
Why?
|
| DNA, Algal | 1 | 2024 | 3 | 0.060 |
Why?
|
| Kelp | 1 | 2024 | 2 | 0.060 |
Why?
|
| Early Medical Intervention | 1 | 2024 | 20 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 84 | 0.050 |
Why?
|
| Administration, Intravaginal | 1 | 2024 | 12 | 0.050 |
Why?
|
| Chloroplasts | 1 | 2024 | 8 | 0.050 |
Why?
|
| South Carolina | 1 | 2024 | 15 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2187 | 0.050 |
Why?
|
| Virginia | 1 | 2024 | 27 | 0.050 |
Why?
|
| Malawi | 1 | 2023 | 9 | 0.050 |
Why?
|
| RNA Transport | 1 | 2024 | 31 | 0.050 |
Why?
|
| Anger | 1 | 2024 | 21 | 0.050 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2023 | 19 | 0.050 |
Why?
|
| Loneliness | 1 | 2024 | 18 | 0.050 |
Why?
|
| Ectopic Gene Expression | 1 | 2023 | 1 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2003 | 29 | 0.050 |
Why?
|
| Homosexuality, Female | 1 | 2003 | 22 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2024 | 54 | 0.050 |
Why?
|
| Cytokinesis | 1 | 2023 | 41 | 0.050 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2023 | 62 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 414 | 0.050 |
Why?
|
| Powders | 1 | 2022 | 21 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 615 | 0.050 |
Why?
|
| Micronutrients | 1 | 2022 | 20 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 136 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2009 | 544 | 0.050 |
Why?
|
| Phylogeny | 1 | 2024 | 386 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 221 | 0.050 |
Why?
|
| Language | 1 | 2024 | 154 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2025 | 531 | 0.050 |
Why?
|
| Spouses | 1 | 2022 | 40 | 0.050 |
Why?
|
| Transcriptome | 1 | 2025 | 398 | 0.040 |
Why?
|
| Polyadenylation | 1 | 2022 | 51 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2022 | 191 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2021 | 77 | 0.040 |
Why?
|
| Hospitals | 1 | 2024 | 385 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2020 | 13 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 41 | 0.040 |
Why?
|
| Lower Extremity Deformities, Congenital | 1 | 2020 | 1 | 0.040 |
Why?
|
| Placenta Previa | 1 | 2020 | 1 | 0.040 |
Why?
|
| Anoctamins | 1 | 2020 | 2 | 0.040 |
Why?
|
| Cicatrix | 1 | 2021 | 62 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2022 | 234 | 0.040 |
Why?
|
| Glucosyltransferases | 1 | 2020 | 15 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2024 | 446 | 0.040 |
Why?
|
| Pseudopodia | 1 | 2020 | 13 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 36 | 0.040 |
Why?
|
| Lipase | 1 | 2020 | 52 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2020 | 240 | 0.040 |
Why?
|
| Endosomes | 1 | 2021 | 180 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 198 | 0.040 |
Why?
|
| HIV | 1 | 2020 | 67 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 797 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 404 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 790 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 151 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 622 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 87 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2021 | 419 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2020 | 160 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2011 | 527 | 0.040 |
Why?
|
| Siblings | 1 | 2018 | 38 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 400 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 193 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 180 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 327 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 1159 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2022 | 905 | 0.030 |
Why?
|
| Serbia | 1 | 2017 | 5 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2017 | 42 | 0.030 |
Why?
|
| Baltimore | 1 | 2016 | 14 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2017 | 51 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 370 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 121 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 178 | 0.030 |
Why?
|
| Haplotypes | 1 | 2017 | 131 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1380 | 0.030 |
Why?
|
| Quality of Life | 1 | 2003 | 1254 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 449 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 161 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 1329 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1638 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1469 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 404 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2130 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 348 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 734 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 101 | 0.020 |
Why?
|
| ORAI1 Protein | 1 | 2010 | 4 | 0.020 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Thapsigargin | 1 | 2010 | 17 | 0.020 |
Why?
|
| Reproductive Medicine | 1 | 2010 | 5 | 0.020 |
Why?
|
| Social Values | 1 | 2010 | 16 | 0.020 |
Why?
|
| TRPC Cation Channels | 1 | 2010 | 13 | 0.020 |
Why?
|
| Boron Compounds | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cell Size | 1 | 2010 | 41 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 133 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 317 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2010 | 138 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2009 | 110 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 272 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 285 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1267 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2010 | 917 | 0.010 |
Why?
|
| Wales | 1 | 2003 | 1 | 0.010 |
Why?
|
| England | 1 | 2003 | 28 | 0.010 |
Why?
|
| Prejudice | 1 | 2003 | 61 | 0.010 |
Why?
|
| Self-Injurious Behavior | 1 | 2003 | 48 | 0.010 |
Why?
|
| Social Behavior | 1 | 2003 | 84 | 0.010 |
Why?
|
| Life Style | 1 | 2003 | 320 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 321 | 0.010 |
Why?
|